Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Injection port

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    34 result(s) found for: Injection port. Displaying page 2 of 2.
    « Previous 1  2 
    EudraCT Number: 2020-006144-18 Sponsor Protocol Number: FIRE-9/PORT Start Date*: 2021-10-05
    Sponsor Name:Charité Universitätsmedizin Berlin
    Full Title: Post-resection/ablation chemotherapy in patients with metastatic colorectal cancer (FIRE-9 - PORT / AIO-KRK-0418) Prospective, randomized, open, multicenter Phase III trial to investigate the eff...
    Medical condition: Metastatic colorectal cancer after definite interventional therapy of all lesions
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-001012-68 Sponsor Protocol Number: CA182-006 Start Date*: 2007-04-17
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Randomized 2-Arm, Open Label, Phase II Study of BMS-582664, Administered Orally At A Dose of 800 mg Daily or Doxorubicin Administered Intravenously At A Dose of 60 mg/m2 Every 3 Weeks In Patients...
    Medical condition: Unresectable, advanced or metastatic hepatocellular carcinoma
    Disease: Version SOC Term Classification Code Term Level
    8.1 10019828 Hepatocellular carcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2013-003453-13 Sponsor Protocol Number: CE01-301 Start Date*: 2014-06-18
    Sponsor Name:Cempra Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-Blind, Multi-Center Study to Evaluate the Efficacy and Safety of Intravenous to Oral Solithromycin (CEM-101) Compared to Intravenous to Oral Moxifloxacin in the Treatment of Ad...
    Medical condition: Community-Acquired Bacterial Pneumonia
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004862 10010120 Community acquired pneumonia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) BG (Completed) LV (Completed) DE (Completed) ES (Completed) RO (Completed) SK (Completed) NL (Completed) SI (Completed)
    Trial results: View results
    EudraCT Number: 2009-013099-38 Sponsor Protocol Number: ML22011 Start Date*: 2010-09-24
    Sponsor Name:Klinikum der Universität München, Anstalt des öffentlichen Rechts vertreten durch den Vorstand
    Full Title: Sequential first-line therapy in metastatic colorectal cancer with Capecitabine/FUFA, Irinotecan and Bevacizumab - Capecitabine/FUFA plus Bevacizumab versus Capecitabine/FUFA plus Irinotecan plus...
    Medical condition: metastatic colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-005169-63 Sponsor Protocol Number: NAB-BC-3781-3101 Start Date*: 2016-01-12
    Sponsor Name:Nabriva Therapeutics AG
    Full Title: A Phase 3, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Lefamulin (BC 3781) Versus Moxifloxacin (With or Without Adjunctive Linezolid) in Adults With Community...
    Medical condition: Community-Acquired Bacterial Pneumonia
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004862 10004051 Bacterial pneumonia, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) HU (Completed) LV (Completed) PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2009-017270-21 Sponsor Protocol Number: TCD11420 Start Date*: 2010-04-28
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: Randomized phase 2 study of gemcitabine/cisplatin with or without SAR240550 (BSI-201), a PARP1 inhibitor, in patients with stage IV non-small cell lung cancer
    Medical condition: Non-small cell lung cancer stage IV.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10029522 Non-small cell lung cancer stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) ES (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-002120-24 Sponsor Protocol Number: OP-104 Start Date*: 2017-12-14
    Sponsor Name:Oncopeptides AB
    Full Title: An Open-Label Phase 1/2a Study of the Safety and Efficacy of Melflufen and Dexamethasone in Combination with either Bortezomib or Daratumumab in Patients with Relapsed or Relapsed-Refractory Multip...
    Medical condition: Patients with Relapsed or Relapsed-Refractory Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004851 10028229 Multiple myelomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) ES (Prematurely Ended) PL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-000293-28 Sponsor Protocol Number: AVB500-OC-004 Start Date*: 2021-09-07
    Sponsor Name:Aravive, Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Adaptive, Placebo/Paclitaxel-Controlled Study of AVB S6 500 in Combination with Paclitaxel in Patients with Platinum-Resistant Recurrent Ovarian Cancer
    Medical condition: Platinum-Resistant Recurrent Ovarian Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Prematurely Ended) PL (Prematurely Ended) CZ (Completed) IT (Prematurely Ended) DE (Completed) BE (Prematurely Ended) GR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-019255-22 Sponsor Protocol Number: 20090321 (EFC11553) Start Date*: 2010-08-06
    Sponsor Name:BiPar Sciences, Inc.
    Full Title: Randomized Phase 3 Trial of Gemcitabine/Carboplatin With or Without BSI-201 (SAR240550) (a PARP1 Inhibitor) in Patients with Previously Untreated Stage IV Squamous Non Small Cell Lung Cancer (NSCLC)
    Medical condition: Squamous Non Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    12.1 10029522 Non-small cell lung cancer stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed) NL (Completed) IT (Completed) DE (Completed) ES (Completed) GB (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2021-004067-28 Sponsor Protocol Number: MO43576 Start Date*: 2021-12-07
    Sponsor Name:F. HOFFMANN - LA ROCHE LTD.
    Full Title: A RANDOMIZED, MULTICENTER, OPEN-LABEL CROSS-OVER STUDY TO EVALUATE PARTICIPANT AND HEALTHCARE PROFESSIONAL REPORTED PREFERENCE FOR SUBCUTANEOUS ATEZOLIZUMAB COMPARED WITH INTRAVENOUS ATEZOLIZUMAB F...
    Medical condition: Non-Small Cell Lung Cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) ES (Ongoing) FI (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2016-004282-31 Sponsor Protocol Number: V14-11056 Start Date*: 2017-03-15
    Sponsor Name:Vivolux AB
    Full Title: VLX1570 and Low-Dose Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma: A Clinical and Correlative Phase 1/2 Study
    Medical condition: Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10028228 Multiple myeloma LLT
    16.1 100000004851 10028229 Multiple myelomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-004349-35 Sponsor Protocol Number: 7001 Start Date*: 2021-02-02
    Sponsor Name:Klinisk Forskningsenhed, Medicinsk Afdeling, Hæmatologisk Afsnit, Sygehus Lillebælt, Vejle Sygehus
    Full Title: Melphalan flufenamide (melflufen) and Dexamethasone re-induction in Daratumumab-refractory Multiple Myeloma as an Adjunct to Continued Daratumumab (MERMAID)
    Medical condition: Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-005674-11 Sponsor Protocol Number: ADVL1412 Start Date*: 2015-04-08
    Sponsor Name:National Cancer Institute
    Full Title: A PHASE 1/2 STUDY OF NIVOLUMAB (IND# 124729) IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH RECURRENT OR REFRACTORY SOLID TUMORS AS A SINGLE AGENT AND IN COMBINATION WITH IPILIMUMAB
    Medical condition: •Childhood Solid Neoplasm •Recurrent Childhood Rhabdomyosarcoma •Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor •Recurrent Neuroblastoma •Recurrent Osteosarcoma •Recurrent ...
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10031296 Osteosarcoma recurrent PT
    17.1 10005329 - Blood and lymphatic system disorders 10025319 Lymphomas Hodgkin's disease HLGT
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029600 Non-Hodgkin's lymphoma recurrent PT
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066595 Neuroblastoma recurrent PT
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015564 Ewing's sarcoma recurrent PT
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10039027 Rhabdomyosarcoma recurrent PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2019-002345-37 Sponsor Protocol Number: MK7902-012 Start Date*: 2020-03-04
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
    Full Title: A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) with Pembrolizumab (MK-3475) in Combination wi...
    Medical condition: Incurable/Non-metastatic Hepatocellular Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073071 Hepatocellular carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) DK (Trial now transitioned) DE (Trial now transitioned) FR (Trial now transitioned) HU (Trial now transitioned) NL (Completed) PT (Trial now transitioned) IE (Trial now transitioned) GB (GB - no longer in EU/EEA) IT (Trial now transitioned) NO (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2 
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jun 13 12:11:47 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA